Trials Sponsors Conditions Drugs Pricing

Conditions

Integrin αVβ3 Positive Tumors

Outcome Measures

Primary Outcomes (1)

StandarStandardized uptake value of 177Lu-AB-3PRGD2 in normal organs and tumors.
The semiquantitative analysis will be performed by the same person for all the cases, and the standardized uptake value at each time point in normal organs and tumors will be measured.
1 year

Secondary Outcomes (1)

Adverse events collection
2 months

Study Arms (1)

1.48 GBq of 177Lu-AB-3PRGD2

EXPERIMENTAL

The patients were intravenously injected with the dose about 1.48GBq (40 mCi) of 177Lu-AB-3PRGD2 and underwent 68Ga-RGD PET/CT scans before and after the treatment.

Drug: 1.48 GBq of 177Lu-AB-3PRGD2

Interventions

1.48 GBq of 177Lu-AB-3PRGD2Drug

accepted intravenous injection of 177Lu-AB-3PRGD2

1.48 GBq of 177Lu-AB-3PRGD2

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 80 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

patients with clear pathological diagnosis and ineffective or progressing clinical conventional treatment;
tumor lesions with high RGD untake confirmed on 68Ga-RGD PET/CT within one week before the injection of 177Lu-AB-3PRGD2;

Sponsors & Collaborators

Peking Union Medical College Hospital
Otherlead

Study Sites (1)

Peking Union Medical College Hospital

Beijing, Beijing Municipality, 100730, China

RECRUITING

Zhaohui Zhu, MDCONTACT86-13611093752 13611093752@163.com

Guochang Wang, MDCONTACT86-18516822732 guochang1007@163.com

Study Officials

Zhaohui Zhu, MD
Peking Union Medical College Hospital
PRINCIPAL INVESTIGATOR

Central Study Contacts

Zhaohui Zhu, MD

CONTACT

86-13611093752 13611093752@163.com

Guochang Wang, MD

CONTACT

86-18516822732

Study Design

Study Type: interventional
Phase: early phase 1
Allocation: NA
Masking: NONE
Purpose: TREATMENT
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

August 13, 2021

First Posted

August 19, 2021

Study Start

October 1, 2021

Actual (reported)

Primary Completion

October 30, 2024

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

177Lu-AB-3PRGD2 in Patients With Integrin αVβ3 Positive Tumors

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (1)

1.48 GBq of 177Lu-AB-3PRGD2

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (1)

1.48 GBq of 177Lu-AB-3PRGD2

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations